XM does not provide services to residents of the United States of America.
S
S

SwissPrime

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss Prime Site: Ongoing Portfolio Streamlining With Sales Of CHF 275 To 300 Mln Expected By Year End

BRIEF-Swiss Prime Site: Ongoing Portfolio Streamlining With Sales Of CHF 275 To 300 Mln Expected By Year End Nov 28 (Reuters) - SWISS PRIME SITE AG SPSN.S : ENFORCEABLE BUILDING PERMITS FOR JELMOLI BUILDING AND «YOND CAMPUS» AND FURTHER PORTFOLIO STREAMLINING THROUGH PROPERTY SALES ONGOING PORTFOLIO STREAMLINING WITH SALES OF CHF 275 TO 300 MILLI
S

Top of the Street: TotalEnergies, Henkel, Arkema, SPS, Segro

BUZZ-Top of the Street: TotalEnergies, Henkel, Arkema, SPS, Segro A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Exane BNP Paribas says TotalEnergies TTEF.PA modest valuation premium comes into question after a year where quarterly results "tended towards disappointment" - cuts the stock to "neutral" from "outperform" ** J.P.Morgan raises Henkel HNKG.DE to "overweight" from "neutral", seeing upside risk to top and bottom lines as Henkel's premiumization
A
J
S
S

Swiss Prime Site FY EBIT Margin Up To 76.3%

BRIEF-Swiss Prime Site FY EBIT Margin Up To 76.3% Nov 13 (Reuters) - SWISS PRIME SITE AG SPSN.S : SWISS PRIME SITE SOLUTIONS INVESTMENT FUND COMMERCIAL ENDS 2023/2024 FINANCIAL YEAR WITH 9.7% GROWTH IN RENTS AND A HIGHER DIVIDEND IN 2023/2024 FINANCIAL YEAR, SPSS IFC RECORDED A 1.9% INCREASE IN ADJUSTED NET REVENUE TO CHF 13.3 MILLION FY EBIT MARGI
S

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F

Barclays sees cheap debt helping Swiss real estate earnings

BUZZ-Barclays sees cheap debt helping Swiss real estate earnings ** Barclays starts Swiss real estate companies PSP Swiss Property PSPN.S with "overweight" and Swiss Prime Site SPSN.S with "equal weight", saying cheap debt in Switzerland should help earnings ** The broker believes the low cost of debt in Switzerland is advantageous, as earnings are
S
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.